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Estrogen receptorThe placenta produces a wide number of molecules that play essential roles in the establishment and main-
tenance of pregnancy. In this context, leptin has emerged as an important player in reproduction. The synthe-
sis of leptin in normal trophoblastic cells is regulated by different endogenous biochemical agents, but the
regulation of placental leptin expression is still poorly understood. We have previously reported that 17β-
estradiol (E2) up-regulates placental leptin expression. To improve the understanding of estrogen receptor
mechanisms in regulating leptin gene expression, in the current study we examined the effect of
membrane-constrained E2 conjugate, E-BSA, on leptin expression in human placental cells. We have found
that leptin expression was induced by E-BSA both in BeWo cells and human placental explants, suggesting
that E2 also exerts its effects through membrane receptors. Moreover E-BSA rapidly activated different
MAPKs and AKT pathways, and these pathways were involved in E2 induced placental leptin expression.
On the other hand we demonstrated the presence of ERα associated to the plasma membrane of BeWo
cells. We showed that E2 genomic and nongenomic actions could be mediated by ERα. Supporting this
idea, the downregulation of ERα level through a speciﬁc siRNA, decreased E-BSA effects on leptin expression.
Taken together, these results provide new evidence of the mechanisms whereby E2 regulates leptin expres-
sion in placenta and support the importance of leptin in placental physiology.
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Steroids play an important role in the growth, differentiation,
metabolism, reproduction, and morphogenesis of higher organ-
isms. Particularly, its actions are required for the development
and maintenance of reproductive tissues [1]. In addition to their
physiological function, steroid hormones also play a crucial role
in many pathological processes, including endocrine, cancerous,
and metabolic diseases.
The most potent and dominant estrogen in humans is 17β-estradiol
(E2) [2]. Estradiol exerts its actions through twomembers of the nuclear
receptor superfamily, estrogen receptor (ER)α and ERβ, and a G
protein-coupled membrane receptor, GPR30 [3]. Mechanisms by
which ERα and ERβ bind ligand, dimerize, associate with coactivators
or corepressors, and regulate gene transcription through binding to
target genes, are well-known and are typically referred to as “genomic”
actions [4]. ER-dependent activation of gene expression also involves
DNA-boundER that subsequently interactswith other DNA-bound tran-
scriptions factors and direct ER-transcription factor (protein–protein)
interactions where ER does not bind promoter DNA [5].
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mediates rapid cellular effects (non-genomic or extranuclear path-
ways) [5]. Estradiol rapidly activates several protein kinases [e.g.,
MAPKs, phosphotidylinositol 3-kinase (PI3K), and protein kinase C
(PKC)] and phosphatases, as well as the release of several cyclic
amines (cAMP, cGMP) and calcium, in a variety of cell types [6]. It is
now ﬁrmly established that estrogen and all sex steroid receptors
exist in discrete cellular pools outside the nucleus. Estrogen receptors
have been localized to the plasma membrane where both ERα and
ERβ function in a wide variety of cells and organs. In ligand-
dependent fashion, each ER pool contributes to the overall, integrated
effects of estrogens producing biological outcomes. Both ERα and
ERβ, the two ER isoforms, localize in many cells to the plasma mem-
brane and to cytoplasmic organelles including mitochondria and the
endoplasmic reticulum [7].
The blastocyst development and implantation is governed by an
extremely complicated but cooperative interplay of various cellular
factors and biomolecules, which are regulated in a deﬁned spatio
temporal fashion. One of the important aspects of blastocyst implan-
tation is the involvement of regulatory molecules, primarily embryo-
trophic factors, which encompass second messengers, transcription
factors, proteases, growth factors and cytokines [8].
In particular, leptin has been proposed to play a relevant role in
implantation and in placenta growth and survival during pregnancy
[9–11]. Leptin hormone, the product of the LEP gene, is a 16000 MW
non-glycosylated polypeptide of 146 amino acids discovered in
1994 by Zhang et al. [12].
In humans, the placenta is a signiﬁcant source of maternal circu-
lating leptin, with levels in the second and third trimesters being up
to 200% of those in the ﬁrst trimester or in the non-gravid situation
[13]. Many physiological roles have been suggested for leptin in
human pregnancy. Both leptin and leptin receptors have been identi-
ﬁed in the placental syncytiotrophoblast, which suggests the poten-
tial for autocrine and paracrine mechanisms. Leptin also activated
the release of proinﬂammatory cytokines and prostaglandins from
human placental explants, further implicating leptin as a modulator
of placental endocrine function. On the other hand, deregulation of
leptin metabolism and/or leptin function in the placenta may be im-
plicated in the pathogenesis of various disorders during pregnancy,
such as recurrent miscarriage, gestational diabetes, intrauterine
growth retardation, and preeclampsia [14,15].
The complete regulation of leptin production in the placenta is still
poorly understood. Previous work demonstrated that hCG and cAMP
enhances leptin expression through a crosstalk between PKA and
MAPK signaling pathways [16,17].
Human placenta is known to synthesize estrogens during preg-
nancy [18], in association with the cytotrophoblast invasion [19,20].
Moreover, there is evidence to suggest that placentally derived estro-
gen may play an autocrine role in trophoblast differentiation [21,22].
Estrogens have been reported to regulate leptin expression by acting
on a portion of the estrogen response element in the leptin promoter
[23]. The presence of estrogen receptor in primate trophoblast [22] sug-
gests that, this is an estrogen receptor-mediatedphenomenon. Estrogen
receptor ER α and β proteins have also been localized in nuclei of cul-
tured human syncytiotrophoblast cells using immunohistochemistry
[22].
Although these ﬁndings suggest the importance of estrogens in
leptin biosynthesis, the mechanisms that mediate leptin expression
by estrogen in human placenta remain undeﬁned. In our previous
work [24,25], we showed that E2 indeed upregulates leptin expres-
sion in human placental cells probably involving genomic and nonge-
nomic action by a crosstalk between ERα and the MAPK and PI3K
signal transduction pathways. To improve the understanding of estro-
gen receptor mechanisms in regulating placental leptin expression,
we here examined the effect of membrane-constrained E2 conjugate,
E-BSA, on leptin expression in human placental cells. Our presentresults suggest that E2, a key regulator of leptin expression in placen-
ta, involves ERα membrane associated via nonclassical estrogen re-
ceptor pathway.
2. Materials and methods
2.1. Cell culture and treatments
The human choriocarcinoma cell line BeWo was grown in 45%
Dulbecco Modiﬁed Eagle Medium (DMEM) and 45% HAM F-12
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf serum
(FCS), 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine
(Invitrogen), and 1 mM sodium pyruvate (Sigma Chemical Company,
St. Louis, MO) at 37 °C in 5% CO2.
The effect of 17β-estradiol (E2; Sigma) was previously tested at
different doses and 10 or 100 nM E2 was used in subsequent experi-
ments [24]. The antiestrogen ICI 182,780 (AstraZeneca, UK, London)
was used to assay the speciﬁcity of estrogen effects. Membrane estro-
gen actions were evidenced incubating with estradiol covalently
linked to BSA (E-BSA, β-Estradiol 6-(O-carboxymethyl)oxime:BSA;
Sigma). E-BSA was ﬁltered prior to use in order to eliminate free E2
according with a previously described method [26]. Brieﬂy, 900 μl of
E-BSA (400 μM in estradiol dissolved in 50 mM Tris–HCl pH 8.5)
was added to a centrifugal ﬁlter unit with a MW cut-off of 3,000
(Millipore, Billerica, MA) and subjected to centrifugation at
13000×g for 30 min. The retained fraction was washed 3 times
with buffer and recovered. Volume was adjusted to 900 μl. The efﬁca-
cy of ﬁltration to remove free E2 was veriﬁed by Stevis et al. [26].
The speciﬁc PI3K inhibitors Wortmannin (0.1 μM) and LY-294,002
(1 μM), the MEK inhibitor PD98059 (50 μM), the p38-MAPK inhibitor
SB 203580 (5 μM) and the JNK inhibitor SP600125 (5 μM) (Sigma)
were also used. Treatments were performed in DMEM-F12 media
without phenol red and supplemented with 1% charcoal stripped
FCS unless otherwise stated. Serum present in incubation media
was reduced from 10% to 1% to lower non-speciﬁc effects.
2.2. Placental explants collection and processing
Human placentas (n=15) were obtained after cesarean section
or vaginal delivery following normal term pregnancies and immedi-
ately suspended in ice-cold phosphate-buffered saline (PBS) and
transported to the laboratory, where they were washed 2–3 times
in sterile PBS to remove excess blood. Villous tissue free of visible in-
farct, calciﬁcation, or hematoma was sampled from at least ﬁve cot-
yledons at a distance midway between the chorionic and basal
plates. These core parts of cotyledons were cut into multiple cubic
segments (10–15 mg wet weight) and thoroughly rinsed with cold
DMEM-F12 medium. None of the donor patients suffered from anoma-
lous pregnancy. Samples were obtained under informed consent, and
the study was approved by the Hospital Universitario Virgen Macarena
(Seville, Spain) ethics committee.
2.3. Treatments of placental explants
Placental explants were randomly distributed in tubes containing
1 ml of DMEM-F12 medium without FCS (n=1 explant/tube, 3 repli-
cates per treatment). Placental explants were maintained in a shaking
water bath at 37 °C during 5 min to equilibrate temperature and incu-
bated in the samemedium supplemented or not with E2 or E-BSA. For
leptin analysis by western blot or qRT-PCR, placental explants were
incubated during 4 h and for signaling experiments they were incu-
bated during 10 min as indicated in each Legend. When indicated
pretreatment with ICI 182,780 or pharmacological inhibitors of sig-
naling pathways were performed during 20 min. Explants were re-
moved from the bath, centrifuged for 2 min at 2000 g at 4 °C and
resuspended in 500 μl of lysis buffer (1 x PBS, 1% Nonidet P-40, 0.5%
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phenylmethanesulfonyl ﬂuoride (PMSF)) during 30 min at 4 °C on an
orbital shaker and later centrifuged at 10000×g for 20 min. Superna-
tants were analyzed by Western blot.
For real-time PCR, after thoroughly washing with PBS, the ex-
plants were immediately frozen at−80 °C and stored until extraction
of total RNA.
2.4. Membrane isolation
Membrane fractions were isolated by sucrose centrifugation
according with a previously described method [27]. Brieﬂy, BeWo
cells were grown on 100 mm dishes in DMEM-F12 plus 1% FCS for
48 h, were washed with icecold PBS and scraped into 0.75 mL sucrose
buffer (50 mM Tris, 1 nM EDTA, 200 mM sucrose, 4 mM NaHPO4,
1 μM Na3VO4, 1 μM NaF). Cells were homogenized by passing the
sample forty times through a syringe needle. Homogenates were
spun at 1000×g at 4 °C. The pellet was resuspended in solubilization
buffer (10 mM Tris–HCl pH 7.4, 1 mM EDTA, 0.5% Triton X-100 plus
protease and phosphatase inhibitors) and labeled “nuclear.” Superna-
tant was spun at 20,000×g for 75 min at 4 °C. The pellet was resus-
pended in solubilization buffer and labeled “membrane” and
supernatant was labeled “cytoplasm.” All the fractions were analyzed
by Western blot.
2.5. Western blot analysis
Total cell lysates were prepared in lysis buffer. The lysates were
centrifuged at 10,000×g for 10 min to remove cellular debris. The
protein concentration of the supernatant was determined by Bradford
[28], using bovine serum albumin (BSA) as standard. Lysates were
mixed with Laemmli´s sample buffer containing 2% SDS and 30 mM
β-mercaptoethanol, boiled for 5 min, separated by SDS-PAGE on a
12% gel, and electrophoretically transferred to a nitrocellulose mem-
brane (Hybond, Amersham Pharmacia, Buckinghamshire, UK). Mem-
branes were equilibrated in 1x PBS and non-speciﬁc binding sites
were blocked by 5% non-fat milk in PBS at room temperature for
1 h. Membranes were then immunoblotted with polyclonal rabbit
anti-human leptin Y20 (1:1000; Santa Cruz Biotechnology, Santa
Cruz, CA), with polyclonal rabbit anti-phospho-mitogen-activated
protein kinase (MAPK) kinase 1 and 2 (MEK1/2) (Ser217/Ser221;
1:3000; Sigma), with polyclonal rabbit anti-phospho-MAPK 1 and 2
(ERK1/2) (Thr202/Tyr204; 1:3000; Sigma), with polyclonal mouse
anti-phospho-AKT (Ser 472/473) antibody (1:3000; BD Biosciences
Pharmingen, NJ), with monoclonal mouse anti-phospho-p38MAPK
(Thr180/Tyr182; 28B10; 1:3000; Cell Signaling Technology, Danvers,
MA), with monoclonal mouse anti-phospho-pSAPK/JNK (Thr183/
Tyr185; G9; 1:3000; Cell Signaling Technology), with polyclonal rab-
bit anti ERα (1:500; Santa Cruz), with polyclonal rabbit anti ERβ
(1:500; Santa Cruz), with polyclonal rabbit anti HDAC1 (1:2000;
Santa Cruz), or with polyclonal rabbit anti G-protein β subunit
(1:1000; Santa Cruz), as indicated in each ﬁgure.
Loading controls were performed by immunoblotting the same
membranes with polyclonal rabbit anti-actin (1:1000; Sigma), with
monoclonal mouse anti-α tubulin (1:1000; Sigma), with polyclonal
rabbit anti-total-MAPK kinase 1 and 2 (MEK 1/2; 1:3000; Sigma),
with polyclonal rabbit anti-total-MAPK 1 and 2 (ERK 1/2; 1:3000;
Sigma) or with polyclonal rabbit anti-total-AKT antibody (1:3000;
Sigma).
Bound antibodieswere detected using horseradish peroxidase-linked
donkey anti-rabbit IgG (1:10000; Amersham Pharmacia) or peroxidase-
linked sheep anti-mouse IgG (1:10000; Amersham Pharmacia) and visu-
alized by the Amersham Pharmacia ECL Chemiluminescence signaling
system and a Bio-Imaging Analyzer Fujiﬁlm LAS-1000. Quantiﬁcation of
protein bands was performed by densitometry using Scion Image soft-
ware (Scion Corporation, Washington, DC).2.6. Plasmids
The luciferase (Luc) reporter construct pL1951 is based on pGL-3
basic vector. Theywere kindly provided byOksanaGavrilova (Bethesda,
MD) [29]. pRSV-βgal contains the β-galactosidase gene under the
control of the Rous sarcoma virus (RSV) promoter and was used to
normalize the efﬁciency of individual transfections.
The plasmid ERE-Luc is an ERE (estrogen responsive element) pro-
moter driven luciferase reporter plasmid and was kindly provided by
Dr. Adalí Pecci (FCEN-UBA, Buenos Aires) [30].
The Sh2 vector produces an intracellular short hairpin (sh) RNA to
mediate ERα mRNA degradation through formation of the ‘RNA-
induced silencing complex.’ It was kindly provided by Dr. Yunus
Luqmani (Faculty of Pharmacy, Kuwait University) [31]. It is based
on pSingle-tTS-shRNA plasmid (Clontech, Mountain View, CA), and
contains the sequence 5′ GATTGGCCAGTACCAATGATTCAAGAGAT-
CATTGGTACTGGCCAATC 3′ cloned into Xho I and HindIII sites, under
the control of the tetracycline-inducible pTRE-U6 promoter.
To perform transient transfection assays, plasmids were puriﬁed
using the Maxipreps Wizard kit (Promega Co., Madison, WI), and
the concentration of DNA was estimated spectrophotometrically.
2.7. Transient transfection experiments
For transient transfection experiments, BeWo cells were plated at
a density of 2.5×105 cells/ml onto six-well dishes containing 2 ml of
DMEM-F12 plus 10% FCS. Cells were incubated for 24 h. Medium was
replaced and transfection of cells was performed according to the
standard liposome-mediated method.
When reporter plasmids were used, the sensitivity of the method
was determined in this cell type, performing a standard dose of re-
porter plasmid vs. light emission (data not shown). Typically 5 μg of
the Luc reporter, 5 μg of pRSV-βgal internal control construct and/or
5 μg of each expression plasmid were transfected using 5 μl of
LipofectAMINE (Life Technologies, Inc., Grand Island, NY). The medium
was replaced after 5 h with DMEM-F12 1% charcoal stripped FCS as
indicated in each ﬁgure, plus the addition of the different effectors.
Transfection analysis was performed in duplicate in at least three
independent experiments.
Transfection of cells with Sh2 plasmid was performed according to
the method previously described, using 5 μg of Sh2/well. Two days
after transfection, the medium was replaced with DMEM-F12 10% con-
taining 500 μg/ml G418 (Sigma). A standard dose–response curve was
performed to evaluate cell sensitivity to G418 (data not shown).
Cell derived clones were serially expanded and passed at least 10
times in G418 containing medium before using for analysis. Expres-
sion of ERα shRNA was induced incubating cells with DMEM-F12 1%
charcoal stripped FCS containing 5 μg/ml doxycycline (Pﬁzer, New
York, NY) during 48 h.
2.8. Assays for Luc and β-galactosidase activities
Luc activity in cell lysates was measured using the Luciferase Assay
System (Promega). Cells were washed with PBS and harvested 48 h
after the transfection procedure using 50 μl of lysis buffer. Cell extracts
were centrifuged and 30 μl of the supernatant were mixed with 50 μl
of Luc assay buffer. Luc activity was measured with a junior lumin-
ometer (Hidex, Turku, Finland). β-galactosidase activity was assayed
using 1 mg of o-nitrophenyl β-D-galactopyranoside (AmResco, Solon,
OH) as the substrate in buffer Z (60 mM Na2HPO4, 40 mM NaH2PO4,
10 mM KCl, 1 mMMgSO4, 0.07% β-mercaptoethanol) and incubated at
37 °C until yellow staining. The product was determined by absorption
at 420 nm. This valuewas used to correct variations in transfection efﬁ-
ciency. Luc results were calculated as the ratio of Luc activity per unit of
β-galactosidase activity. Duplicate samples were analyzed for each data
point.
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Abundance of leptin mRNA was determined by qRT-PCR. Total RNA
was extracted from placental explants using TRISURE reagent, according
to the manufacture instructions (Bioline Co., Essex, UK). Concentration
and purity of the isolated RNA were estimated spectrophotometrically
at 260 and 280 nm. For cDNA synthesis, 5 μg of total RNA was reverse
transcribed at 55 °C during 1 h using the Transcriptor ﬁrst Strand cDNA
synthesis Kit (Roche, Indianapolis, IN). Quantitative real-time PCR was
performed using the following primers based on the sequences of the
National Center for Biotechnology Information GenBank database: lep-
tin: forward, 5′GAACCCTGTGCGGATTCTT 3′; reverse, 5′ CCAGGTCGTTG-
GATATTTGG 3′; and cyclophilin: forward, 5′ CTTCCCCGATGAGAACTTCA
3′; reverse, 5′ TCTTGGTGCTCTCCACCTTC 3′. Quantitative RT-PCR Master
Mix Reagent kit was obtained from Qiagen (SensiMixTM Plus SYBR Kit),
and PCRs were performed on a MJ Mini BioRAD gradient thermal cycler
(Bio-Rad, Hercules, CA). A typical reaction contained 10 μM of forward
and reverse primer, 3 μl of cDNA, and the ﬁnal reaction volume was
25 μl. The reaction was initiated by preheating at 95 °C for 10 min. Sub-
sequently, 41 ampliﬁcation cycles were carried out as follows: denatur-
ation 15 sec at 95 °C, annealing 30 sec at 58 °C min and extension
30 sec at 72 °C. The threshold cycle (CT) from eachwell was determined
by the BioRAD CFXManager Program. Relative quantiﬁcation was calcu-
lated using the 2-ΔΔCT method. For the treated samples, evaluation of 2-
ΔΔCT indicates the fold change in gene expression, normalized to a house-
keeping gene (cyclophylin), and relative to the untreated control.
2.10. Immunoﬂuorescence
BeWo cells were grown on coverslips overnight in DMEM-F12
plus 10% FCS. Then were washed three times in PBS and ﬁxed 5 min
at RT with 2.0% paraformaldehyde, 0.5% Nonidet P-40 (NP-40) and
0.15 M sucrose in PBS pH 7.4; freshly prepared, according a previous
described method [32]. At the end of the ﬁxation period, the cells
were washed three times with PBS, and blocked 1-h at RT with 10%
BSA in PBS. The primary antibodies were diluted in 0.5% BSA in PBS
and were added to the cells ON at 4 °C; next, the cells were washed
six times PBS. A Cy3-labeled antirabbit IgG (Invitrogen) was added
to the cells in the dark for 6 h at 4 °C. Washed cells were stained
with Hoechst 33342, mounted with Mowiol 4–88 (Sigma), and stored
in the dark at 4 °C until examined for ﬂuorescence. Photomicrographs
were taken using a Nikon Eclipse E600W microscope (Nikon, Tokyo,
Japan) equipped with a Y-FL epiﬂuorescence attachment and a digital
camera (Nikon Coolpix 5000) or using an Eclipse E800 Nikon C1 laser
confocal microscope.
2.11. Data analysis
Experiments were repeated separately at least three times to as-
sure reproducible results. Results are expressed as mean±standard
error (S.E.M) in arbitrary units (a.u.). Arbitrary units were calculated
as normalized band intensity in Western blot analysis or normalized
Luc activity in reporter assays, where control values were taken as
1. Statistical analysis was performed using the Graph Pad Prism com-
puter program (GraphPad Software, San Diego, CA). Statistical signif-
icance was assessed by ANOVA followed by different post hoc tests, as
indicated in each ﬁgure. A p-valueb0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Estradiol-BSA enhances endogenous leptin expression in placental
cells
We have previously observed that E2 was able to induce leptin ex-
pression not only in BeWo cells but also in human placental explants.Our results strongly suggest that E2 action probably involves both ge-
nomic and nongenomic actions [24]. In order to evidence the involve-
ment of membrane receptors in E2 signaling, we aimed to study the
effect of membrane-constrained E2 conjugate, E-BSA, on leptin ex-
pression in human placental cells.
As seen in Fig. 1A, E-BSA enhanced leptin expression in BeWo cells
as determined by Western blot analysis. This effect was dose depen-
dent, reaching a 2.2-fold maximal increase at 100 nM. We next per-
formed transient transfection assays with a vector containing the
regulatory region of leptin gene from −1951 bp fused to the Luc re-
porter gene (pL1951). As shown in Fig. 1B, in transfected BeWo
cells, treatment with 10 nM E-BSA for 48 h induced a 5.6-fold maxi-
mal increase in Luc activity. A control treatment with 100 nM E2
was included; it signiﬁcantly enhanced leptin expression as previous-
ly reported [24]. In order to analyze whether E-BSA stimulates leptin
at the transcriptional level in a more physiological model, additional
experiments were performed in placental explants. Fig. 1C shows
that E-BSA signiﬁcantly enhanced leptin mRNA expression, measured
by qRT-PCR in human placental explants. Maximal effect was
achieved at 10 nM with a 3.9-fold increase. Control treatment with
0.1 nM E2 signiﬁcantly enhanced leptin expression.
To conﬁrm that E-BSA is not a membrane-permeable compound,
BeWo cells were transfected with a luciferase reporter construct driv-
en by a minimal promoter containing tandem repeats of a canonical
ERE, and then stimulated with E2 or E-BSA as indicated for 48 h
(Fig. 1D). Compared with control, E2 triggered over a 3.7-fold increase
in ERE-driven Luc activity, whereas E-BSA had no effect.
Taken together, these results suggest that E-BSA increases placen-
tal leptin expression through estrogen membrane-initiated actions.
3.2. Estradiol-BSA activates multiple signal transduction pathways
Estrogen action mediated by membrane receptors are frequently
associated with the activation of many protein-kinase cascades [33].
So, our next aim was to investigate whether E-BSA could activate dif-
ferent signaling transduction pathways in placental cells.
As shown in Fig. 2, ERK1/2, AKT, p38-MAPK and JNK phosphoryla-
tion were increased with E-BSA treatment in n BeWo cells, and these
effects were dose dependent. On the other hand, E-BSA increased
MEK, ERK1/2 and AKT phosphorylation in placental explants, but
did not affect p38-MAPK and JNK phosphorylation (Fig. 3).
These results suggest that E-BSA is able to activate MAPKs and
PI3K signal transduction pathways in placental cells.
3.3. Estradiol-BSA involves multiple signaling pathways in the induction
of leptin expression
Recent evidence suggest that estrogen membrane initiated actions
may indirectly inﬂuence gene expression, through the activation of
signal transduction pathways that eventually act on target transcrip-
tion factors [2]. E-BSA enhanced leptin expression and also activated
different signaling pathways in placental cells, therefore we decided
to analyze if those signaling pathways are involved in E-BSA induc-
tion of leptin expression.
Results obtained in transfected BeWo cells (Fig. 4A), showed that
leptin promoter activity enhanced by E-BSA was signiﬁcantly reduced
when cells were pretreated with pharmacological inhibitors of MEK
(50 μM PD98059), p38-MAPK (5 μM SB 20358), JNK (5 μM SP600125)
and PI3K (0.1 μM Wortmannin and 1 μM LY-294,002) pathways. It
was observed that basal leptin expression seemed to be dependent on
JNK activation as the treatment with SP600125 alone signiﬁcantly de-
creased promoter activity.
Similar experiments were performed in human placental explants,
a more physiological model. In these experiments explants were pre-
treated with the same pharmacological inhibitors and then incubated
with 10 nM E-BSA for 4 h. Treatments with all the inhibitors tested
Fig. 1. E-BSA enhances leptin expression in placental cells. A, BeWo cells were plated in complete DMEM-F12 media supplemented with 1% charcoal stripped FCS and incubated
during 48 h with different doses of E-BSA. Cell extracts were prepared as indicated in Materials and Methods. Proteins were separated on SDS-PAGE gels, and leptin expression
was determined byWestern blot analysis. Molecular weights were estimated using standard protein markers. Loading controls were performed by immunoblotting the same mem-
branes with anti-β-actin. Bands densitometry is shown in lower panels. Molecular mass (kDa) is indicated at the left of the blot. B, BeWo cells were transiently transfected with
pL1951 plasmid construction and treated with E2 or E-BSA as indicated during 48 h in DMEM-F12 media supplemented with 1% charcoal stripped FCS. Luc activity was measured
in cellular extracts and normalized to β-galactosidase activity. C, Placental explants were processed as previously described and treated with E2 or E-BSA during 4 h. Total RNA was
extracted as described in Materials and Methods. Leptin mRNA was quantiﬁed with real-time RT-PCR. Cyclophilin was used as internal standard. D, BeWo cells were transiently
transfected with ERE-Luc plasmid construction and treated with E2 or E-BSA as indicated during 48 h in DMEM-F12 media supplemented with 1% charcoal stripped FCS. Luc activity
was measured in cellular extracts and normalized to β-galactosidase activity. Results are expressed as mean±SEM for three independent experiments performed in duplicates.
Statistical analyses were performed by ANOVA. Asterisks indicate signiﬁcant differences from the control according to Dunnett's multiple comparison post hoc test. * pb0.05 vs.
control. a.u.: arbitrary units.
904 Y.P. Gambino et al. / Biochimica et Biophysica Acta 1823 (2012) 900–910signiﬁcantly blocked the effect of E-BSA on leptin expression mea-
sured by qRT-PCR (Fig. 4B), suggesting that MAPKs and PI3K path-
ways are involved in E-BSA leptin induction.
3.4. ERα is localized both in nucleus and plasma membranes of BeWo
cells
Estrogen receptors have been localized to the plasma membrane
where both ERα and ERβ function in a wide variety of cells and organs
[7]. The physiologic role of these plasmamembrane binding sites for es-
trogens is currently under intense investigation. We decided to investi-
gate if ERα and ERβ estrogen receptors are present in plasma
membrane of BeWo cells by two different experimental approaches:
Western blot of subcellular fractions and immunoﬂuorescence.
In total sample the 66 KDa band corresponding to ERα was ob-
served. Analyzing subcellular fractions obtained by sucrose gradients
of BeWo cells, we detected ERα in nuclear and also in membrane frac-
tions (Fig. 5A). Three detectable bands were observed between 66
and 50 KDa, probably due to partial degradation or to fractionation
artifacts.
By the other side, ERβ appears to be mainly nuclear, although it
has been slightly detected in cytosol of BeWo cells (Fig. 5A).
In order to evidence whether the treatment with E2 or E-BSA alters
the distribution of ERα, similar cellular fractionation experiments were
performed in the presence of the hormone. As it can be seen in Fig. 5B
(Western blot results) and in 5 C (relative ERα expression), ERαlocalization was not modiﬁed after 48 h of incubation in the presence of
100 nM of E2 or E-BSA. The time of the treatment was choose according
previous results, where it was demonstrated that the presence of E2 or
E-BSA produced a maximal increase in leptin expression at 48 h of treat-
ment [24].
HDAC1 and G-protein β subunit detection were used as control of
quality of nucleus and membrane fractions respectively. As it can be
seen in Figs. 5A and 5B both proteins were only revealed in their
speciﬁc compartments.
By a different experimental approach as immunoﬂuorescence,
similar results were obtained. ERα was detected mainly in nucleus
and in plasma membrane of BeWo cells (Fig. 6A) meanwhile ERβ is
predominantly nuclear (Fig. 6B). Immunoﬂuorescence results were
conﬁrmed by confocal microscopy (Fig. 6D and 6E).
Negative controls in the absence of primary antibodies were also
performed (Fig. 6C and 6F).
These results strongly suggest that ERα is localized both in nucleus
and plasma membrane of trophoblastic cells, and could be involved in
estrogen regulation of placental leptin expression.3.5. Estradiol action probably involves ERα membrane receptors
Finally, we analyzed if ERα membrane receptor could mediate
membrane-initiated estrogen actions involved in placental leptin
expression.
DR
el
at
iv
e 
p 
p3
8-
 M
AP
K
p p38-MAPK
tubulin
0
1
2
3
38 KDa 
50 KDa
0
2
4
R
el
at
iv
e 
pJ
NK
54 KDa
46 KDa 
50 KDa 
p JNK
tubulin
C
44/42 KDa
44/42 KDa
50 KDa
p ERK
ERK
tubulin
R
el
at
iv
e 
pE
RK
 
0
2
4
6
8
E-BSA (nM) 1 10 102
56 KDa
56 KDa
50 KDa 
p AKT
AKT
tubulin
R
el
at
iv
e 
pA
KT
0
1
2
3
A B
* *
*
*
α α
α α
0 E-BSA (nM) 1 10 1020
E-BSA (nM) 1 10 1020 E-BSA (nM) 1 10 1020
Fig. 2. E-BSA activates multiple signaling pathways in BeWo cells. A–D, BeWo cells were preincubated 18 h in DMEM-F12 media supplemented with charcoal stripped 1% FCS, and
then treated with E-BSA for 15 min. Cell extracts were prepared as indicated in Materials and Methods. ERK1/2 (A), AKT (B), p38-MAPK (C) and JNK (D) phosphorylation were
determined by Western blot as indicated in Materials and Methods. The same membranes were analyzed by immunoblot using anti-total ERK 1/2 or AKT. Loading controls were
performed by immunoblotting the same membranes with anti-α-tubulin as indicated. Band densitometry is shown in lower panel in arbitrary units. Results from a representative
experiment are shown. They are expressed as mean±SEM of two independent experiments. Asterisks indicate signiﬁcant differences from the control according to Dunn's multiple
comparison post hoc test. * pb0.05 vs. control.
R
el
at
iv
e 
p 
p3
8-
 M
AP
K
p p38-MAPK 
tubulin
38 KDa 
50 KDa
0
1
R
el
at
iv
e 
pJ
NK
54 KDa
46 KDa 
50 KDa 
p JNK
tubulin
0
1
D E
56 KDa
56 KDa 
50 KDa 
p AKT
AKT
tubulin
R
el
at
iv
e 
pA
KT
0
1
2
3
CB
44 KDa
42 KDa
44KDa
42 KDa
50 KDa
p ERK
ERK
tubulin
46 KDa
46 KDa
50 KDa
p MEK
MEK
tubulin
A
R
el
at
iv
e 
pM
EK
E-BSA(nM) 0          1 10 1020
1
2
3
R
el
at
iv
e 
pE
RK
0
1
2
3
*
α α α
α
α
E-BSA(nM) 0          1 10 102 E-BSA(nM) 0          1 10 102
E-BSA(nM) 0          1 10 102
E-BSA(nM) 0          1 10 102
Fig. 3. E-BSA activates multiple signaling pathways in placental explants. A–E, Placental explants were processed as previously described and treated with E-BSA for 10 min. MEK
(A), ERK 1/2 (B), AKT (C), p38-MAPK (D) and JNK (E) phosphorylation were determined by Western blot as indicated in Materials and Methods. The same membranes were
analyzed by immunoblot using anti-total MEK, ERK 1/2 or AKT. Loading controls were performed by immunoblotting the same membranes with anti-α-tubulin as indicated. In
Western blot analysis, samples were loaded in a 12% SDS-PAGE. Band densitometry is shown in lower panel in arbitrary units. Results from a representative experiment are
shown. They are expressed as mean±SEM of two independent experiments. Band densitometry is shown in lower panel in arbitrary units. Results from a representative
experiment are shown. They are expressed as mean±SEM of two independent experiments. Asterisks indicate signiﬁcant differences from the control according to Dunn's multiple
comparison post hoc test. * pb0.05 vs. control.
905Y.P. Gambino et al. / Biochimica et Biophysica Acta 1823 (2012) 900–910
*R
el
at
iv
e 
le
pt
in
 e
xp
re
ss
io
n 
(a.
u)
-
E-B
SA PD
PD
 + 
E-B
SA SB
SB
 + 
E-B
SA SP
SP
 + 
E-B
SA W
W 
+ E
-B
SA LY
LY
 + 
E-B
SA
0
1
2
3
4
5
#                                                          
-
E-
BS
A PD
PD
 + 
E-
BS
A SB
SB
 + 
E-B
SA SP
SP
 + 
E-B
SA W
W 
+ E
-B
SA LY
LY
 + 
E-
BS
A
0
1
2
3
4
R
el
at
iv
e 
lu
ci
fe
ra
se
 a
ct
ivi
ty
 (a
.u)
# # #
# #
*
#
A B
RSV gal
pLEP
-1951          +42
LUC
#
#
#
β
Fig. 4. Different signaling pathways are involved in leptin expression induced by E-BSA. A, BeWo cells were transfectedwith pL1951 and were pretreated for 20 min with different phar-
macological inhibitors: 50 μMPD98059 (PD),MEK inhibitor, 5 μMSB203580 (SB), p38-MAPK inhibitor, 5 μMSP600125 (SP), JNK inhibitor, 0.1 μMWortmannin (W) and1 μMLY-294,002
(LY), PI3K inhibitors. Cells were incubated for 48 h with (black bars) or without 1 nM of E-BSA. Cell extracts were prepared as indicated in Materials and Methods and Luc activity was
normalized to β-galactosidase activity. B, Placental explants were pretreated for 20 min with different pharmacological inhibitors: 50 μM PD98059 (PD), MEK inhibitor, 5 μM SB
203580 (SB), p38-MAPK inhibitor, 5 μM SP600125 (SP), JNK inhibitor, 0.1 μM Wortmannin (W) and 1 μM LY-294,002 (LY), PI3K inhibitors. Cells were incubated for 4 h with (black
bars) or without 10 nM of E-BSA. Total RNA was extracted as described in Materials and Methods. Leptin mRNA was quantiﬁed with real-time RT-PCR. Cyclophilin was used as internal
standard. Results are expressed as mean±SEM for three independent experiments performed in triplicates. Statistical analyses were performed by ANOVA. Asterisks indicate signiﬁcant
differences from the control according to Bonferroni's multiple comparison post hoc test. * pb0.05 vs. control, # pb0.05 vs cells treated with E-BSA. a.u.: arbitrary units.
906 Y.P. Gambino et al. / Biochimica et Biophysica Acta 1823 (2012) 900–910The antiestrogen ICI 182,780 was used to assay if E-BSA effects de-
pends on the presence of functional estrogen receptors.When placental
explants were pretreated with 100 nM ICI 182,780, the stimulatory ef-
fect of E-BSA on leptin expression was prevented (Fig. 7A). Moreover,
in the presence of 100 nM ICI 182,780, E-BSA failed to induce ERK 1/2
phosphorylation (Fig. 7B). By the other side 100 nM ICI 182,780 in-
creased AKT phosphorylation, probably due to some agonist effect ofN          M         C                     TA
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Three independent repetitions were performed. a.u.: arbitrary units.this antiestrogen (Fig. 7C). These results suggest that ICI 182,780 can
block some of the effects of E-BSA in placental explants.
In a different experimental approach siRNA silencing against ERα
was carried out. BeWo cells were stable transfected with Sh2 con-
struct to decrease ERα protein. Expression of ERα siRNA was induced
incubating cells with 5 μg/ml doxycycline, which showed no effect on
ERα or ERβ expression in non-transfected BeWo cells (Fig. 8A).Cytosol
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907Y.P. Gambino et al. / Biochimica et Biophysica Acta 1823 (2012) 900–910In Fig. 8B it is shown that ERα siRNA expression produced a
marked reduction in the amount of ERα protein in BeWo cells mea-
sured by Western blot. The ERα silencing was speciﬁc, as ERβ level
was not modiﬁed in Sh2 transfected cells treated with doxycycline.
In Sh2 transfected cells, not induced with doxycycline, the incubation
with 100 nM estradiol or 1–100 nM E-BSA increased leptin promoter
activity (Fig. 8D). Besides, ERα protein was not totally downregulated
when ERα siRNA expression was induced with doxycycline. In this
scenario the treatment with E2 or E-BSA failed to induce leptin ex-
pression (Fig. 8C) and leptin promoter activity (Fig. 8D). On the
other hand, it was previously demonstrated that E-BSA treatment
probably does not exert its effect on leptin expression through an in-
tracellular ER (Fig. 1D). All together these results strongly suggest
that in BeWo cells, the membrane receptor/s involved in E-BSA in-
duced leptin expression could be membrane associated ERα.
4. Discussion
The steroid hormone 17β-estradiol (E2) is an estrogen that regu-
lates growth, differentiation, and function in a wide array of target tis-
sues, including the male and female reproductive tracts, mammary
gland, and skeletal and cardiovascular systems [34]. It exerts some ef-
fects through the action of classical estrogen receptors ERα and ERβ,
which act as ligand-activated transcription factors and regulate gene
expression [33]. In addition, E2 can elicit rapid responses from
membrane-associated receptors, like activation of protein kinase
pathways, which can result in the modiﬁcation of transcriptional ac-
tivity of conventional transcription factors. Thus the cellular effects
of E2 will depend on the speciﬁc receptors expressed and the integra-
tion of their stimulatory and inhibitory signaling events [35].
During human pregnancy, the production of E2 raises eighty fold,
from 0.75 nM preovulatory peak to 60 nM at term. Estradiol inﬂu-
ences various aspects of placental function and fetal development in
humans and primates [36], and plays a role in the regulation of fetal
growth, onset of parturition, placental steroideogenesis, release of
neuropeptides, release of glycoproteins and leptin secretion [37].
Leptin is a key hormone in trophoblast proliferation and survival
[25], that regulates cell proliferation by inhibiting apoptosis [10,11],stimulates protein synthesis [38], and regulates fetal growth and
development [39].
The regulation and physiology of leptin in placenta is largely
unknown, and in particular little is known about the mechanisms
involved in regulation of leptin expression by E2 in placental cells. It
was previously reported that E2 increased leptin production in
cultured human cytotrophoblastic cells from ﬁrst trimester placenta
[37]. Moreover, it was demonstrated that E2 enhanced leptin promoter
activity in JEG-3 cells, suggesting that E2 regulates LEP gene expression
via promoter activation [23]. Those investigations suggest that E2 could
be an important regulator of leptin expression in placental cells. Our
previous results indicated that E2 induces leptin expression not only
in BeWo cells but also in human placental explants probably involving
both soluble and membrane estrogen receptors [24].
In this regard, we aimed to study the regulation of leptin expres-
sion by E-BSA, an estrogen analogue that evidence membrane-
iniciated estrogen actions [40]. We used two experimental models:
BeWo choriocarcinoma cells and human placental explants. BeWo
cells maintain many characteristics of human trophoblast cells and
have been widely used to study placental cellular signaling [41–43].
Normal placental explants from healthy donors were also studied to
conﬁrm the physiological relevance of the results.
When the effect of E-BSA on leptin expression was analyzed in
BeWo cells and human placental explants, a signiﬁcant upregulation
was observed. Moreover, we observed that E-BSAwas able to increase
leptin promoter activity and leptin mRNA transcription. These geno-
mics effects could not be attributed to classic nuclear ERs, as E-BSA,
in contrast to E2, failed to stimulate the reporter activity of ERE-Luc
plasmid. These results conﬁrmed the membrane-constraint property
of E-BSA and suggested that its actions are probably triggered by plas-
ma membrane receptors.
We observed that high concentration of E-BSA was less efﬁcient
on leptin expression induction than low concentration in both exper-
imental models. Similar results were obtained with E2 effect on leptin
expression in placental cells [24], and are also in agreement with the
bifasic modulation of human cytotrophoblastic leptin secretion by E2
[37]. The underlying molecular mechanism is not completely under-
stood. It has been proposed that high doses of E2 or E-BSA could
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908 Y.P. Gambino et al. / Biochimica et Biophysica Acta 1823 (2012) 900–910downregulate the expression of estrogen receptors, as observed in
other reproductive tissues, but this hypothesis remains to be studied
in placental cells.
Membrane-initiated actions by E2 could regulate gene expression
through the activation of different signaling pathways such us PLC/PKC; p38/MAPK; JAK/STAT; Pak1; casein kinase I-g2; and sphingosine
kinase [44].
Our results suggest that E-BSA activates MEK-ERK and PI3K signal-
ing pathways both in placental explants and BeWo cells. The activa-
tion of p-38 MAPK and JNK signaling pathways by E-BSA were only
evidenced in BeWo cells. Further experiments will be needed to clar-
ify the differences between these experimental models. Despite these
differences, all the signaling pathways analyzed are probably in-
volved in E-BSA regulation of placental leptin expression as evi-
denced in the pharmacological inhibition experiments.
Our results are in agreement with previous reports, where it has
been shown that E2 can exert rapid non-genomic effects in human
placental explants, inducing ERK 1/2 and AKT phosphorylation. The
blockage of these pathways in BeWo cells prevented the effect of E2
on leptin expression both at protein and transcriptional levels [24].
Various regulatory elements have been identiﬁed within the lep-
tin promoter, e.g., cAMP, estrogen, androgen, insulin and glucocorti-
coid response elements, CCATT/enhancer and SP1 binding sites,
suggesting a direct regulation of leptin expression through different
transcriptional pathways [25]. Several transcription factors that rec-
ognize those regulatory elements could be interacting with nuclear
estrogen receptors or could be modulated by protein kinases activat-
ed by membrane-iniciated estrogen actions, as it has been widely
reported [2]. Further experiments will be needed to understand the
possible mechanisms of integration of membrane signaling and nu-
clear effects of E2 involved in human placental leptin expression.
It is known that E2 exerts its actions through two members of the
nuclear receptor superfamily, estrogen receptor ERα and ERβ, and
also through a G protein coupled membrane receptor, GPR30 [45].
The presence of estrogen receptor in primate trophoblast suggests
that, as in adipose tissue, the effect of estrogen on leptin expression
is an estrogen receptor-mediated phenomenon [46].
Although term placenta has been found to speciﬁcally bind estro-
gens, cellular localization of ERα in trophoblasts remains unclear [36].
Immunohistochemistry in term placenta sections showed that the
ERα was strongly expressed in cytotrophoblast nuclei, lying beneath
trophoblastic syncytium, which showed no staining of the nuclei.
ERα immunoreactivity was also detected in villous vessels and sinu-
soids [36]. By the other side, reverse transcription-polymerase chain
reaction and Western analyses showed the presence of ERα tran-
scripts and protein in BeWo cells. The BeWo cell ER binds to an ERE
consensus sequence, suggesting that these cells express a functional
ER [47].
It has also been reported that human term placental tissues ex-
press ERβ and it was localized in the syncytiotrophoblast layer and
in only few cells of the cytotrophoblast; no staining was observed in
the stromal region. The presence of ERβ mRNA was also detected in
BeWo choriocarcinoma cell line, and its expression –but not the
ERα expression- is down-regulated by E2 [48]. Our results suggest
that BeWo cells express ERβ and it appears to be mainly nuclear, al-
though cytosolic ERβ was also detected by immunoﬂuorescence.
Previous results support the involvement of ERα in placental lep-
tin expression, as the over- expression of ERα in BeWo cells increased
the stimulatory effect of E2 on leptin promoter activity [24]. More-
over, it has been proposed that the expression of ERα, and not of
ERβ, evidenced the stimulatory effect of E2 on leptin expression in
JEG-3 cells [23].
In the present work we showed that BeWo cells express ERα
mainly detected in nucleus and plasma membrane, but also cytosolic
protein was detected by immunoﬂuorescence.
These results are consistent with previous reports of Bukovsky et
al. [36]. They observed that trophoblast cultures derived from normal
placenta exhibited surface ERα expression. Nondividing trophoblast
cells showed cytoplasmic/perinuclear or perinuclear/nuclear ERα im-
munoreactivity, which was accompanied by diminution of cell surface
staining [36].
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909Y.P. Gambino et al. / Biochimica et Biophysica Acta 1823 (2012) 900–910The blockage of E-BSA effects on ERK phosphorylation and leptin
mRNA expression with the antiestrogen ICI 182,780 that ERα could
be the receptor involved in membrane-initiated estrogen actions
that regulate leptin expression in placental cells. Moreover, decreased
expression of ERα through a speciﬁc siRNA signiﬁcantly dimished the
effect of E-BSA on leptin expression.
Membrane initiated estradiol signaling have been reported in the
regulation of rapid cell signaling in the control of sexual receptivity
and in the estrogen positive feedback regulating the LH surge [49].
Our results suggest that leptin physiology may also depend of
membrane-associated estrogen effects.
In the late 1990s was revealed the existence of the receptor
GPR30, a member of the G protein–coupled receptor superfamily
that mediates estrogen-dependent kinase activation as well as tran-
scriptional responses [50]. GPR30 transcripts were reported to be
widely distributed in normal and malignant human tissues, although
there are discrepancies in the reported expression levels in placenta
[50]. Besides, ICI 182,780 is also a GPR30 agonist [50], and can rapidly
induce a signiﬁcant increase in ERK2 and AKT phosphorylation, failing
to block some E2 effects [51,52]. Further experiments will be needed
to analyze if GPR30 is expressed in trophoblastic cells and participates
in E2 up-regulation of placental leptin expression.
5. Conclusions
In summary, in this study, we provide evidence that E-BSA induces
leptin expression through the activation of multiple signaling pathways
910 Y.P. Gambino et al. / Biochimica et Biophysica Acta 1823 (2012) 900–910that could regulate leptin gene expression. The possible mechanism of
regulation of placental leptin expression by E2 is amultifactorial process,
and may depend on the presence, concentration and localization of ERs,
transcription factors, co-regulatory proteins and signal transducers,
among others, as illustrated in the model based in current data shown
in Fig. 9. Our results provide new evidence of the regulatorymechanisms
of placental leptin expression and support the importance of leptin in
reproduction.References
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